Apr 05, 2024
KRAS mutations represent the most commonly encountered driver oncogene, implicated in approximately 25% of all human cancers, with KRASG12D emerging as a predominant isoform, particularly prevalent in pancreatic, colorectal, and non-small cell lung cancers. Despite its frequency, targeting KRASG12D poses distinct c...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper